The US Food and Drug Administration has discussed with vaccine-maker Novavax the need for an additional trial of its Covid-19 vaccine as a post-approval commitment, a source familiar with the matter told CNN.

At FDA, full vaccine approval is the gold standard. The agency was on track to sign off on Novavax’s license by its April 1 target date, according to two people with direct knowledge of the situation who spoke on condition of anonymity to discuss confidential agency matters.

The vaccine is the only protein-based COVID shot still in use in the U.S. This approval would allow the vaccine to stay on the market long-term FRIDAY, April 25, 2025 (HealthDay News) — Novavax’s COVID-19 vaccine could soon receive full approval from the U.